La influencia del posmodernismo cinematográfico en las publicidades audiovisuales

En este trabajo se analiza la influencia del movimiento postmodernista cinematográfico en las publicidades audiovisuales modernas. Se aborda la temática desde una metodología correlacional, donde se busca determinar en qué grado se encuentran presentes los rasgos del postmodernismo en la publicidad. Primeramente, se identificaron las características del movimiento con la intención de comprenderlo mejor y de incorporar sus distinciones para nutrir la investigación. Luego, se realizó una exigente selección de spots publicitarios a considerar para la observación y análisis detallado de los mismos. Se trabajó con una muestra de 20 spots producidos entre 2012 y 2018, con un target segmentado compuesto por hombres y mujeres entre 20 y 30 años; además, la muestra se limitó a rubros indumentaria y calzado, perfumes y desodorantes, bebidas, y servicios de comunicación

La influencia del posmodernismo cinematográfico en las publicidades audiovisuales

Comunicación científica en formato ORAL (Tesina de Grado), realizada en las III Jornadas Internacionales de Investigación, Ciencia y Universidad y las XII Jornadas de Investigación UMaza, en el Bloque de comunicaciones científicas: "CIENCIAS DE LA COMUNICACIÓN", el mismo fue moderado por la Esp. CAROLINA TOMBA. Las jornadas se llevaron adelante desde 19 al 23 de octubre del 2020 en formato totalmente virtual bajo plataforma Zoom y fueron transmitidas por el canal YouTube de la UMaza y el Facebook del Área de Ciencia y Técnica UMaza (Somos Ciencia y Técnica UMaza)

Peri-lead edema and local field potential correlation in post-surgery subthalamic nucleus deep brain stimulation patients

Implanting deep brain stimulation (DBS) electrodes in patients with Parkinson's disease often results in the appearance of a non-infectious, delayed-onset edema that disappears over time. However, the time window between the DBS electrode and DBS stimulating device implant is often used to record local field potentials (LFPs) which are used both to better understand basal ganglia pathophysiology and to improve DBS therapy. In this work, we investigated whether the presence of post-surgery edema correlates with the quality of LFP recordings in eight patients with advanced Parkinson's disease implanted with subthalamic DBS electrodes. The magnetic resonance scans of the brain after 8.5 +/- 1.5 days from the implantation surgery were segmented and the peri-electrode edema volume was calculated for both brain hemispheres. We found a correlation (rho = -0.81, p < 0.0218, Spearman's correlation coefficient) between left side local field potentials of the low beta band (11-20 Hz) and the edema volume of the same side. No other significant differences between the hemispheres were found. Despite the limited sample size, our results suggest that the effect on LFPs may be related to the edema localization, thus indicating a mechanism involving brain networks instead of a simple change in the electrode-tissue interface

Effects of Anacetrapib in Patients with Atherosclerotic Vascular Disease

BACKGROUND: Patients with atherosclerotic vascular disease remain at high risk for cardiovascular events despite effective statin-based treatment of low-density lipoprotein (LDL) cholesterol levels. The inhibition of cholesteryl ester transfer protein (CETP) by anacetrapib reduces LDL cholesterol levels and increases high-density lipoprotein (HDL) cholesterol levels. However, trials of other CETP inhibitors have shown neutral or adverse effects on cardiovascular outcomes. METHODS: We conducted a randomized, double-blind, placebo-controlled trial involving 30,449 adults with atherosclerotic vascular disease who were receiving intensive atorvastatin therapy and who had a mean LDL cholesterol level of 61 mg per deciliter (1.58 mmol per liter), a mean non-HDL cholesterol level of 92 mg per deciliter (2.38 mmol per liter), and a mean HDL cholesterol level of 40 mg per deciliter (1.03 mmol per liter). The patients were assigned to receive either 100 mg of anacetrapib once daily (15,225 patients) or matching placebo (15,224 patients). The primary outcome was the first major coronary event, a composite of coronary death, myocardial infarction, or coronary revascularization. RESULTS: During the median follow-up period of 4.1 years, the primary outcome occurred in significantly fewer patients in the anacetrapib group than in the placebo group (1640 of 15,225 patients [10.8%] vs. 1803 of 15,224 patients [11.8%]; rate ratio, 0.91; 95% confidence interval, 0.85 to 0.97; P=0.004). The relative difference in risk was similar across multiple prespecified subgroups. At the trial midpoint, the mean level of HDL cholesterol was higher by 43 mg per deciliter (1.12 mmol per liter) in the anacetrapib group than in the placebo group (a relative difference of 104%), and the mean level of non-HDL cholesterol was lower by 17 mg per deciliter (0.44 mmol per liter), a relative difference of -18%. There were no significant between-group differences in the risk of death, cancer, or other serious adverse events. CONCLUSIONS: Among patients with atherosclerotic vascular disease who were receiving intensive statin therapy, the use of anacetrapib resulted in a lower incidence of major coronary events than the use of placebo. (Funded by Merck and others; Current Controlled Trials number, ISRCTN48678192 ; ClinicalTrials.gov number, NCT01252953 ; and EudraCT number, 2010-023467-18 .)

Bloque de comunicaciones científicas: Ciencias de la comunicación

REGISTRO AUDIOVISUAL. Bloque de comunicaciones científicas del tema: CIENCIAS DE LA COMUNICACIÓN, realizado en las III Jornadas Internacionales de Investigación, Ciencia y Universidad y las XII Jornadas de Investigación UMaza, el día 22 de octubre del 2020. El bloque fue moderado por la Esp. CAROLINA TOMBA. Las jornadas se llevaron adelante desde 19 al 23 de octubre del 2020 en formato totalmente virtual bajo plataforma Zoom y fueron transmitidas por el canal YouTube de la UMaza y el Facebook del Área de Ciencia y Técnica UMaza (Somos Ciencia y Técnica UMaza). Video editado por JOAQUÍN CIRICA, carrera Lic. en Realización Audiovisual UMaza. NOTA IMPORTANTE: Los autores que aquí se nombran fueron los oradores del bloque, no constituyendo la totalidad de los autores de las comunicaciones científicas presentadas (Para conocer el detalle total de autores, ver los mismos en cada comunicación publicada)

La nascita del commercio e l’organizzazione spaziale della città

li scritti che seguono in questa pubblicazione trattano del Primo Corso di Perfezionamento post-laurea svolto in Italia sulla Progettazione Urbanistica e Architettonica del Commercio Urbano. Il tema d’anno ha riguardato la sistemazione urbana del tratto più rappresentativo di via Toledo e delle aree limitrofe e i risultati positivi sono stati pubblicizzati alla Biennale dello spazio pubblico a Roma e in seno alla comunità europea nell’ambito di una proposta di “Rigenerazione urbana che produca opportunità di sviluppo economico e sociale”. Articolo: Giancarlo Priori La nascita del commercio e l’organizzazione spaziale della città Il tema di questo scritto implica due parole chiave di lettura: città e commercio e il legame principale che le rende dipendenti, ossia l’organizzazione spaziale. Nel nostro paese gli spazi urbani che caratterizzano le grandi città, come i piccoli centri, sono, per antonomasia, luoghi di eccellenza d’identità e di caratterizzazione, sia per la conformazione dei tessuti urbani sia per le relazioni spaziali. In generale, l’organizzazione spaziale è stata certamente configurata assecondando le condizioni e le preesistenze fisiche tanto per quel che riguarda gli orientamenti degli insediamenti primitivi quanto le conformazioni dei siti e questo ha prodotto la creazione di spazi dinamici di collegamento, le strade, e spazi aperti di riposo, le piazze. L’articolo, in sintesi, passa in rassegna le diverse tipologie urbane e architettoniche dell’attività commerciale, dai tempi dei romani, alle piazze delle erbe e frutta, fino ai centri commerciali, passando per i mercati e i grandi magazzin

Animal models and animal-free innovations for cardiovascular research: current status and routes to be explored. Consensus document of the ESC working group on myocardial function and the ESC Working Group on Cellular Biology of the Heart

Cardiovascular diseases represent a major cause of morbidity and mortality, necessitating research to improve diagnostics, and to discover and test novel preventive and curative therapies, all of which warrant experimental models that recapitulate human disease. The translation of basic science results to clinical practice is a challenging task, in particular for complex conditions such as cardiovascular diseases, which often result from multiple risk factors and comorbidities. This difficulty might lead some individuals to question the value of animal research, citing the translational 'valley of death', which largely reflects the fact that studies in rodents are difficult to translate to humans. This is also influenced by the fact that new, human-derived in vitro models can recapitulate aspects of disease processes. However, it would be a mistake to think that animal models do not represent a vital step in the translational pathway as they do provide important pathophysiological insights into disease mechanisms particularly on an organ and systemic level. While stem cell-derived human models have the potential to become key in testing toxicity and effectiveness of new drugs, we need to be realistic, and carefully validate all new human-like disease models. In this position paper, we highlight recent advances in trying to reduce the number of animals for cardiovascular research ranging from stem cell-derived models to in situ modelling of heart properties, bioinformatic models based on large datasets, and state-of-the-art animal models, which show clinically relevant characteristics observed in patients with a cardiovascular disease. We aim to provide a guide to help researchers in their experimental design to translate bench findings to clinical routine taking the replacement, reduction, and refinement (3R) as a guiding concept

Animal models and animal-free innovations for cardiovascular research: current status and routes to be explored. Consensus document of the ESC Working Group on Myocardial Function and the ESC Working Group on Cellular Biology of the Heart

Cardiovascular diseases represent a major cause of morbidity and mortality, necessitating research to improve diagnostics, and to discover and test novel preventive and curative therapies, all of which warrant experimental models that recapitulate human disease. The translation of basic science results to clinical practice is a challenging task, in particular for complex conditions such as cardiovascular diseases, which often result from multiple risk factors and comorbidities. This difficulty might lead some individuals to question the value of animal research, citing the translational 'valley of death', which largely reflects the fact that studies in rodents are difficult to translate to humans. This is also influenced by the fact that new, human-derived in vitro models can recapitulate aspects of disease processes. However, it would be a mistake to think that animal models do not represent a vital step in the translational pathway as they do provide important pathophysiological insights into disease mechanisms particularly on an organ and systemic level. While stem cell-derived human models have the potential to become key in testing toxicity and effectiveness of new drugs, we need to be realistic, and carefully validate all new human-like disease models. In this position paper, we highlight recent advances in trying to reduce the number of animals for cardiovascular research ranging from stem cell-derived models to in situ modelling of heart properties, bioinformatic models based on large datasets, and state-of-the-art animal models, which show clinically relevant characteristics observed in patients with a cardiovascular disease. We aim to provide a guide to help researchers in their experimental design to translate bench findings to clinical routine taking the replacement, reduction, and refinement (3R) as a guiding concept

Animal models and animal-free innovations for cardiovascular research: current status and routes to be explored. Consensus document of the ESC working group on myocardial function and the ESC Working Group on Cellular Biology of the Heart

Cardiovascular diseases represent a major cause of morbidity and mortality, necessitating research to improve diagnostics, and to discover and test novel preventive and curative therapies, all of which warrant experimental models that recapitulate human disease. The translation of basic science results to clinical practice is a challenging task, in particular for complex conditions such as cardiovascular diseases, which often result from multiple risk factors and comorbidities. This difficulty might lead some individuals to question the value of animal research, citing the translational 'valley of death', which largely reflects the fact that studies in rodents are difficult to translate to humans. This is also influenced by the fact that new, human-derived in vitro models can recapitulate aspects of disease processes. However, it would be a mistake to think that animal models do not represent a vital step in the translational pathway as they do provide important pathophysiological insights into disease mechanisms particularly on an organ and systemic level. While stem cell-derived human models have the potential to become key in testing toxicity and effectiveness of new drugs, we need to be realistic, and carefully validate all new human-like disease models. In this position paper, we highlight recent advances in trying to reduce the number of animals for cardiovascular research ranging from stem cell-derived models to in situ modelling of heart properties, bioinformatic models based on large datasets, and state-of-the-art animal models, which show clinically relevant characteristics observed in patients with a cardiovascular disease. We aim to provide a guide to help researchers in their experimental design to translate bench findings to clinical routine taking the replacement, reduction, and refinement (3R) as a guiding concept

Animal models and animal-free innovations for cardiovascular research: current status and routes to be explored. Consensus document of the ESC working group on myocardial function and the ESC Working Group on Cellular Biology of the Heart.

Cardiovascular diseases represent a major cause of morbidity and mortality, necessitating research to improve diagnostics, and to discover and test novel preventive and curative therapies. All of which warrant experimental models that recapitulate human disease. The translation of basic science results to clinical practice is a challenging task. In particular for complex conditions such as cardiovascular diseases, which often result from multiple risk factors and co-morbidities. This difficulty might lead some individuals to question the value of animal research, citing the translational 'valley of death', which largely reflects the fact that studies in rodents are difficult to translate to humans. This is also influenced by the fact that new, human-derived in vitro models can recapitulate aspects of disease processes. However, it would be a mistake to think that animal models cannot provide a vital step in the translational pathway as they do provide important pathophysiological insights into disease mechanisms particularly on a organ and systemic level. While stem cell-derived human models have the potential to become key in testing toxicity and effectiveness of new drugs, we need to be realistic, and carefully validate all new human-like disease models. In this position paper, we highlight recent advances in trying to reduce the number of animals for cardiovascular research ranging from stem cell-derived models to in situ modelling of heart properties, bioinformatic models based on large datasets, and improved current animal models, which show clinically relevant characteristics observed in patients with a cardiovascular disease. We aim to provide a guide to help researchers in their experimental design to translate bench findings to clinical routine taking the replacement, reduction and refinement (3R) as a guiding concept